Navigation Links
Jillian Michaels, 'America's Toughest Trainer,' Announces New Line of Weight-Loss Supplements
Date:6/29/2009

illian Michaels brand," says Empowered Media CEO, Giancarlo Chersich. "We want to provide our customers with a total life solution and this partnership helps us round out our platform. Together, we have developed healthy and innovative natural products that will help consumers manage their weight-loss goals. Since the products are natural, they represent the kind of health and wellness lifestyle that Jillian always promotes. We are looking forward to a long and mutually beneficial relationship."

Jillian Michaels' products will be sold at GNC, Wal-Mart, Walgreens, CVS, Rite-Aid, Target and most chain grocery stores. For more information visit, www.jillianweightloss.com.

About Jillian Michaels

Jillian Michaels is one of the leading health and wellness experts in the country. Perhaps considered one of the most demanding people on the television for her role as trainer and life coach on the NBC hit series The Biggest Loser, Michaels has created a brand name for herself through helping people achieve healthier and happier lives. Every week she motivates nearly 15 million TV viewers, approximately 2 million subscribers to her Web site and daily e-mail newsletter, and many more radio listeners. As a motivator and role model, Jillian has a unique connection with her audience that stems from her own personal journey toward wellness. Before she was a huge TV success, Jillian struggled with her own weight. She was determined to reach her goals - and through dedication and hard work, she did.

About Empowered Media, LLC

Empowered Media, LLC operates the Jillian Michaels health and wellness brand. The company operates as life architects who's sole mission is to inspire individuals to empower themselves to seek healthier active lives. The products marketed are part of the total life solution platform created by Jill
'/>"/>

SOURCE Empowered Media, LLC
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Majesco Entertainment and Interactive Game Group Announce Jillian Michaels Fitness Ultimatum 2009 for Wii(TM)
2. Majesco Entertainment and Interactive Game Group Announce Jillian Michaels Fitness Ultimatum 2009 Ships to Stores October 21st
3. Majesco Entertainment and Interactive Game Group Announce Two New Jillian Michaels Fitness Video Games
4. Cochlear Americas Announces 2008 Graeme Clark Scholarship Winners
5. Mentice, Inc. Announces Appointment of Vice-President, Sales and Marketing, Americas
6. Olympus Corporation of the Americas Names Mark Gumz President & CEO
7. DNA Find in Oregon Is Oldest Yet Discovered in Americas
8. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
9. ExamForce Hires Former (ISC)2 Americas Leader to Head Corporate and Government Sales Efforts
10. Konica Minolta Sensing Americas Announces the Launch of the CM-SA Skin Analysis Software
11. Kari Boiler Named President of Bugaboo Americas

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Linemen especially likely to have metabolic syndr...HealthDay News) -- Exercise alone isn,t enough to ...g at higher risk for a medical condition that can ...Researchers studied linemen at Division I colleges...2 percent had metabolic syndrome, a group of condi...
(Date:12/2/2009)..., , VIRGINIA BEACH, Va., Dec. 2 /PRNewsw...garette. These smokeless cigarettes continue to gr...arket is now available at the PremiumEcigarette - ...ctronic cigarette - at the amazingly low price of ...for people to try the e-cigarette at a very low pr...
(Date:12/2/2009)..., , MONTREAL, Dec. 2 /PRNewswire/ - As pa...around the world, Wyeth, now a part of Pfizer, has...(IUs) of factor concentrates to the World Federati...on ever made to the WFH,s Humanitarian Aid Program...e WFH,s goals. ,, "This donation will directly ...
(Date:12/2/2009)..., , KNOXVILLE, Tenn., Dec. 2 /PRNewswire... presence in Southwest Florida with the acquisitio...LLC (EPN). Since January 2002, EPN has held an ex...ff the emergency facilities at the Downtown Naples...althcare Clinic. EPN also provides the staffing fo...
(Date:12/2/2009)..., EUROECHO 2009 is the official congress of the E...egistered branch of the European Society of Cardio...imaging will be presented. , New case reports w... latest evidence highlighting the role of this new... in imaging techniques, it is likely that non-inva...
Breaking Medicine News(10 mins):Health News:Oversized College Football Players May Face Heart Risks 2Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH 2Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2Health News:Media alert: EUROECHO 2009 2
... regimen combining vinorelbine (Navelbine) and mit...rednisone is effective in the treatment of hormone... treatment should be offered to symptomatic patien...nts who had advanced prostate cancer, the investig...
...ion caused by the heart's inability to pump effici... and weaker. An estimated 5 million Americans ha...hin five years. It can be caused by high blood pre...ducing inflammation, helping to better control the...
...er whether hormone replacement therapy is safe and...tudy examines the pros and cons of this controvers... combined HRT therapy for five years. All the wome...uld not use HRT therapy because of the associated ...
...women more severely than men and greatly impacts t...University of Massachusetts Medical School, analyz...attention for chronic cough and a control group of... chronic cough group reported physical and extreme...
...nges from 10 percent to 25 percent, with the peak ...ars. Some reports suggest as many as 14 percent of...5 percent of women use antidepressants during preg... for pregnant women. However, most of these studie...
...ing a soft plastic tube or catheter into the linin...st undergo training for two weeks and are then abl...m the comfort of their home. Hemodialysis patients... kidney disease would choose home-based peritoneal...
Other Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/2/2009)... , NANJING, China, Dec. 2 /PRNewswire-...r the "Company") (NYSE: SCR ), a leading pharmac...anufacturing, and marketing of branded,generic and...ted that its,subsidiary Jiangsu Yanshen Biological...s suspended production of all its products in orde...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewsw...cluding a late-breaking presentation on Tasigna...ic myeloid leukemia, demonstrate the strength of t... care of patients. ,, The new data, at the 51s...ing and Exposition, highlight the company,s curren...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 1Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 2Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 3Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 1Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 2
...nces announced,today, the initiation of a Phase 2 ...he treatment and management of acute infectious,mo...apeutics for the,treatment for this debilitating c...n-Barr virus (EBV), "Valomaciclovir has shown a b...ibition of viral replication of herpes zoster and ...
...gel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today a... PFE ), has begun a Phase 1 clinical trial of an,...kinase inhibitor, R343,for the treatment of allerg...Rigel,s clinical portfolio., Under the terms of t...will receive a $5 million milestone payment from P...
Other Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
Alloclassic Hip
Perfecta RS Stems
S-ROM Femoral Stems - XX-Long Length Stems 36mm Neck with 21mm Calcar Replacement + Lat Neck
S-ROM Femoral Stems - Long Length Stems Standard 36mm Neck
Medicine Products: